EUVIMEDEUVIMED entdecken
Crossref

Personalized Tumor Membrane Vesicle Vaccine Immunotherapy for Head and Neck Squamous Cell Carcinoma (HNSCC) 2253480

Ramireddy Bommireddy, Christopher Pack, Sampath Ramachandiran, Kristen Jacobsen, Shaker Reddy, Nicole Schmitt, Conor Steuer, Nabil Saba, Periasamy Selvaraj, Dong Shin

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Ramireddy Bommireddy und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Head and neck cancer exhibits a high degree of heterogeneity, with lack of common therapeutic targets. We have developed an autologous therapeutic cancer vaccine approach using tumor-membrane vesicles (TMVs) prepared from surgically removed tumor tissue incorporated with glycolipid-anchored immunostimulatory molecules with B7.1 and IL-12. We hypothesize that tumors resistant to immune checkpoint inhibitor therapy (cold tumors) will be turned into hot tumor by TMV vaccine and induce response to anti-PD-1 antibody therapy in advanced metastatic HNSCC patients. Our phase 1 clinical trial (NCT06868433) will evaluate a novel personalized immunotherapy approach using TMV prepared from the patients’ own surgically excised tumor tissue and modifying them by attaching GPI-B7-1 and GPI-IL-12 as immune boosting molecules.

Methods

A total of 10 HNSCC tumor specimens were collected (0.29-1.23 grams) and graded for cellularity by a pathologist. Tumor samples were then homogenized, and homogenate was ultracentrifuged over a sucrose gradient to enrich TMV. TMV preparations were incorporated with GPI-B7-1 and GPI-IL-12 to generate the TMV vaccine. We used established murine oral cancer models to investigate the protective anti-tumor immune response of TMV vaccine in combination with anti-PD1 antibody therapy. Spleens were flash frozen in liquid nitrogen and stored in -80oC for RNA-seq analysis.

Results

TMV yields were 2.5 — 5 mg/gram of tissue from patient samples. Further refinement of the TMV production process yielded up to 6 mg of TMV/gram of tumor. We have just begun enrolling patients in the phase 1 trial and banking tumor for vaccine production if they ever become eligible to receive the vaccine to treat recurrent/metastatic disease. RNA-seq data from mouse model suggests that the TMV vaccine showed synergistic activity when combined with anti-PD1 antibody, with enhanced T cell responses.

Conclusion

TMV vaccine synergizes with anti-PD1 in inducing anti-tumor responses. Funding Source Supported by NIH/NCI 1R01CA262123-01A1 to DMS & PS. Topic Categories Vaccines and Immunotherapy (VAC)

Zitieren

APA

Bommireddy, R., Pack, C., Ramachandiran, S., Jacobsen, K., Reddy, S., Schmitt, N., Steuer, C., Saba, N., Selvaraj, P., & Shin, D. (2026). Personalized Tumor Membrane Vesicle Vaccine Immunotherapy for Head and Neck Squamous Cell Carcinoma (HNSCC) 2253480. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.173

Vancouver

Bommireddy R, Pack C, Ramachandiran S, Jacobsen K, Reddy S, Schmitt N, et al. Personalized Tumor Membrane Vesicle Vaccine Immunotherapy for Head and Neck Squamous Cell Carcinoma (HNSCC) 2253480. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.173

BibTeX
@article{Bommireddy2026,
  author = {Bommireddy, Ramireddy and Pack, Christopher and Ramachandiran, Sampath and Jacobsen, Kristen and Reddy, Shaker and Schmitt, Nicole and Steuer, Conor and Saba, Nabil and Selvaraj, Periasamy and Shin, Dong},
  title = {Personalized Tumor Membrane Vesicle Vaccine Immunotherapy for Head and Neck Squamous Cell Carcinoma (HNSCC) 2253480},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.173}
}
Kostenlos starten →